SK288119B6 - Von Willebrand Factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide - Google Patents

Von Willebrand Factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide Download PDF

Info

Publication number
SK288119B6
SK288119B6 SK802-2003A SK8022003A SK288119B6 SK 288119 B6 SK288119 B6 SK 288119B6 SK 8022003 A SK8022003 A SK 8022003A SK 288119 B6 SK288119 B6 SK 288119B6
Authority
SK
Slovakia
Prior art keywords
vwf
polypeptide
seq
protease
activity
Prior art date
Application number
SK802-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK8022003A3 (en
Inventor
Bernhard Laemmle
Helena Elisabeth Schaller-Gerritsen
Miha Furlan
Peter Turecek
Hans-Peter Schwarz
Friedrich Scheiflinger
Gerhard Antoine
Randolf Kerschbaumer
Luigina Tagliavacca
Klaus Zimmermann
Dirk Voelkel
Original Assignee
Baxter Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27110398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK288119(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Aktiengesellschaft filed Critical Baxter Aktiengesellschaft
Publication of SK8022003A3 publication Critical patent/SK8022003A3/sk
Publication of SK288119B6 publication Critical patent/SK288119B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SK802-2003A 2000-11-22 2001-11-20 Von Willebrand Factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide SK288119B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72125400A 2000-11-22 2000-11-22
US09/833,328 US6926894B2 (en) 2000-11-22 2001-04-12 Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
PCT/EP2001/013391 WO2002042441A2 (en) 2000-11-22 2001-11-20 VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE

Publications (2)

Publication Number Publication Date
SK8022003A3 SK8022003A3 (en) 2004-04-06
SK288119B6 true SK288119B6 (sk) 2013-09-03

Family

ID=27110398

Family Applications (1)

Application Number Title Priority Date Filing Date
SK802-2003A SK288119B6 (sk) 2000-11-22 2001-11-20 Von Willebrand Factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide

Country Status (15)

Country Link
US (7) US6926894B2 (hu)
EP (1) EP1346034B1 (hu)
AT (1) ATE423194T1 (hu)
AU (1) AU2002218306A1 (hu)
CZ (1) CZ305602B6 (hu)
DE (1) DE60137710D1 (hu)
DK (1) DK1346034T3 (hu)
ES (1) ES2322126T3 (hu)
HU (1) HU227996B1 (hu)
NZ (1) NZ526616A (hu)
PT (1) PT1346034E (hu)
RU (1) RU2003118441A (hu)
SI (1) SI1346034T1 (hu)
SK (1) SK288119B6 (hu)
WO (1) WO2002042441A2 (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
WO2003016492A2 (en) * 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
DE20213920U1 (de) 2002-07-03 2003-01-16 Boehm Martina Diagnostikum zum Nachweis der den von Willebrand-Faktorspaltenden Aktivität von ADAMTS13
AU2012203101B2 (en) * 2002-09-25 2014-10-02 Km Biologics Co., Ltd. Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same
CA2499926C (en) * 2002-09-25 2013-06-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Antibody against von willebrand factor cleaving enzyme and assay system using the same
US20040185042A1 (en) * 2003-03-20 2004-09-23 Friedrich Scheiflinger Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies
US7763430B2 (en) 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
CA2550939A1 (en) 2003-12-22 2005-07-07 Mitsubishi Kagaku Iatron, Inc. Method of detecting thrombosis by measuring von willebrand factor-cleaving protease
EP1568782A1 (de) * 2004-02-25 2005-08-31 Clemens Bockmeyer Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen
DE602004027314D1 (de) * 2004-07-19 2010-07-01 American Diagnostica Inc Verfahren zur messung von adamts13-aktivität auf der blutplättchenoberfläche.
US20080138837A1 (en) * 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
WO2006133955A1 (en) 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
US7893616B2 (en) * 2006-02-27 2011-02-22 Ohio State University Process to determine enzyme activity
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
PT2574677T (pt) 2007-12-27 2017-10-19 Baxalta Inc Processos para cultura de células
KR101756354B1 (ko) 2009-07-31 2017-07-26 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
EA024267B1 (ru) 2009-09-21 2016-09-30 Баксалта Инкорпорейтид Стабилизированные жидкие и лиофилизированные композиции adamts13
JP6138683B2 (ja) 2010-07-08 2017-05-31 バクスアルタ ゲーエムベーハー 細胞培養による組換え型ａｄａｍｔｓ１３産生方法
EP2652491B1 (en) 2010-12-15 2017-11-29 Baxalta GmbH Eluate collection using conductivity gradient
AU2012255027B2 (en) 2011-05-19 2015-09-24 Takeda Pharmaceutical Company Limited Detection of circulating ADAMTS13-antibody complexes
KR102006151B1 (ko) 2012-11-27 2019-10-10 삼성디스플레이 주식회사 터치를 인식하고 전기 촉각 자극을 제공하는 표시 장치 및 그 구동 방법
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
WO2016186994A1 (en) * 2015-05-15 2016-11-24 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of thrombotic microangiopathy
KR20230079461A (ko) 2016-08-04 2023-06-07 다케다 파머수티컬 컴패니 리미티드 급성 폐 손상 및/또는 급성 호흡 곤란 증후군에서 혈관폐색 위기의 치료, 개선 및/또는 예방을 위한 adamts13의 용도
FR3069156B1 (fr) * 2017-07-21 2019-08-09 Universite de Bordeaux Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques
BR112022019817A2 (pt) 2020-04-02 2022-12-06 Takeda Pharmaceuticals Co Variante de adamts13, composições e usos das mesmas
US20230201319A1 (en) 2020-05-22 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT406867B (de) * 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
US20010049106A1 (en) * 2000-04-27 2001-12-06 Leonard Buckbinder ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US7070532B2 (en) * 2003-08-26 2006-07-04 General Motors Corporation Planetary transmission having a rotating-type torque-transmitting mechanism with a stationary piston

Also Published As

Publication number Publication date
RU2003118441A (ru) 2004-12-10
CZ20031718A3 (cs) 2004-07-14
US20090017467A1 (en) 2009-01-15
US20090203110A1 (en) 2009-08-13
US20080176312A1 (en) 2008-07-24
US20050266528A1 (en) 2005-12-01
CZ305602B6 (cs) 2016-01-06
ATE423194T1 (de) 2009-03-15
SI1346034T1 (sl) 2009-08-31
DE60137710D1 (de) 2009-04-02
AU2002218306A1 (en) 2002-06-03
NZ526616A (en) 2005-04-29
US8703429B2 (en) 2014-04-22
US8703426B2 (en) 2014-04-22
US9309506B2 (en) 2016-04-12
HUP0400588A3 (en) 2006-01-30
US20170065686A1 (en) 2017-03-09
US7501117B2 (en) 2009-03-10
HU227996B1 (hu) 2012-08-28
HUP0400588A2 (hu) 2004-06-28
US20140335071A1 (en) 2014-11-13
SK8022003A3 (en) 2004-04-06
EP1346034A2 (en) 2003-09-24
US7910094B2 (en) 2011-03-22
WO2002042441A2 (en) 2002-05-30
US20020136713A1 (en) 2002-09-26
WO2002042441A3 (en) 2002-08-08
ES2322126T3 (es) 2009-06-17
PT1346034E (pt) 2009-05-05
US6926894B2 (en) 2005-08-09
EP1346034B1 (en) 2009-02-18
DK1346034T3 (da) 2009-05-11

Similar Documents

Publication Publication Date Title
EP1346034B1 (en) VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE
US5202253A (en) Monoclonal antibody specific for protein C and antibody purification method
AU699748B2 (en) Recombinant HK2 polypeptide
US5043429A (en) Protein fragments containing Factor VIII binding domain of von Willebrand Factor
CA2222419A1 (en) A novel form of dipeptidylpeptidase iv (cd26) found in human serum, antibodies thereto, and uses therefor
EP0407544B1 (en) Monoclonal antibody against protein c
ES2268961B1 (es) Nueva proteina epcr soluble de origen no proteolitico y su uso.
BORGEL et al. Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the γ-carboxyglutamic acid-rich domain
Malm et al. Expression of completely γ‐carboxylated and β‐hydroxylated recombinant human vitamin‐K‐dependent protein S with full biological activity
Smyth et al. Expression of recombinant human Met-ase-1: a NK cell-specific granzyme
McGraw et al. Antigenic determinant in human coagulation factor IX: immunological screening and DNA sequence analysis of recombinant phage map a monoclonal antibody to residues 111 through 132 of the zymogen
US5500344A (en) Serine protease and uses thereof
ZA200304741B (en) Von willebrand factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide.
US20050043254A1 (en) Novel serine protease inhibitory protein mt0039

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: BAXALTA GMBH, GLATTPARK (OPFIKON), CH

Free format text: FORMER OWNER: BAXALTA INNOVATIONS GMBH, VIENNA, AT

Effective date: 20160314

Owner name: BAXALTA INCORPORATED, BANNOCKBURN, IL, US

Free format text: FORMER OWNER: BAXALTA INNOVATIONS GMBH, VIENNA, AT

Effective date: 20160314

TC4A Change of owner's name

Owner name: BAXALTA INNOVATIONS GMBH, VIENNA, AT

Effective date: 20160816

TE4A Change of owner's address

Owner name: BAXALTA GMBH, ZUG, CH

Effective date: 20180808

Owner name: BAXALTA INCORPORATED, BANNOCKBURN, IL, US

Effective date: 20180808

MK4A Patent expired

Expiry date: 20211120